CLINICAL_TRIALS trial_result · 2025-06-06

Clinical Trial Update: Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration [Phase 4]

Phase 4 trial evaluating faricimab in high-frequency aflibercept-treated neovascular age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Medical University of Graz | Conditions: Neovascular Age-related Macular Degeneration | Phase 4 | Status: COMPLETED